Hu et al. showed that tumor cells develop resistance to CDK9 inhibitors due to the CDK9 L156F mutation, which disrupts the binding of the inhibitor to CDK9 through steric hindrance, thereby affecting the stability and catalytic activity of the CDK9 protein[164]. This evidence concerns the gene CDK9 and neoplasm.